Lakefront Biotherapeutics NV (LKFT) stock
LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$34.39−0.40 (-1.15%)
Close on Nov 17, 2026Market cap $2.27BP/E 6.4Yield –
Lakefront Biotherapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Lakefront Biotherapeutics's pe ratio was 6.1× on Nov 11, 2026, against 24.1× a year earlier. Over the last 5 years it ranged from 4.9× to 83.4×, with a median of 24.9×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 6.1× | −18.7 |
| 2025 | Dec 31, 2025 | 24.9× | +16.6 |
| 2024 | Dec 31, 2024 | 8.3× | −19.2 |
| 2021 | Feb 26, 2021 | 27.4× | −5.1 |
| 2020 | Dec 31, 2020 | 32.5× | −42.4 |
| 2018 | Feb 28, 2018 | 74.9× | +6.4 |
| 2017 | Dec 29, 2017 | 68.4× | – |
See a number that looks wrong?